Eli Lilly's New Parkinson's Drug Shows Significant Promise in Clinical Trials
Eli Lilly’s experimental drug, LY344867, has shown notable success in a mid-stage clinical trial. The medication, aimed at slowing Parkinson's disease progression, revealed significant improvements in motor function among early-stage patients. Over 12 months, 180 patients participated, with those on LY344867 experiencing a 35% reduction in motor symptoms. The promising data was presented at a major medical conference.
Aug, 17 2024